Analyzing Gene Regions That May Interact With the Effectiveness of High Blood Pressure Drugs

NCT00573092 | Withdrawn

• 2 other identifiers: 1411R01HL085251-01A1
• Study Type: observational
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

High blood pressure is one of the most common health problems in the United States. There are many drug treatment options for high blood pressure, but these medications are not always effective. People with treated high blood pressure can still suffer from other serious cardiovascular health problems, including heart attack, sudden death, or stroke. Genetic variations may cause some people to be more susceptible to these cardiovascular outcomes despite treatment. This study will identify new gene regions that may influence the effectiveness of high blood pressure drugs in preventing the above mentioned cardiovascular conditions.

Conditions

Myocardial Infarction; Cerebrovascular Accident; Death, Sudden, Cardiac

Keywords

Cardiovascular Epidemiology; Genomics; Genome-Wide Association Study

Outcome Measures

Primary Outcomes (1)

• Genomic regions for each of the four major drug classes that influence drug and gene interaction

  Measured at completion of genetic analysis

Secondary Outcomes (1)

• Ethnic-specific genetic variations for each of the four major drug classes that influence drug and gene interaction

  Measured at completion of genetic analysis

Study Arms (1)

1

Data and specimens from three large population-based studies of heart attack, sudden death, and stroke in people treated for high blood pressure with one of the four major classes of high blood pressure drugs

Eligibility Criteria

• Age: 30 Years - 79 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Data and specimens for this study will be collected from three population-based studies: Group Health population, Cardiovascular Heart Study, and Jackson Heart Study. The Group Health population will provide new DNA samples; the Cardiovascular Heart and Jackson Heart studies will provide existing DNA specimens to replicate the study findings from the Group Health population. The Cardiovascular Heart Study involves Americans over the age of 65. The Jackson Heart Study is a cardiovascular disease study in African Americans.

You may qualify if:

• Experience of a first heart attack, stroke, or sudden death
• Member of the Group Health Center (GHC) treated for high blood pressure
• Enrolled at least 1 year in one of the three study populations
• Treated for high blood pressure with one of the four major classes of high blood pressure drugs (diuretics, beta-blockers, ACE inhibitors, or calcium antagonists)

Sponsors & Collaborators

• University of Washington: lead
• National Heart, Lung, and Blood Institute (NHLBI): collaborator

Study Sites (1)

Cardiovascular Health Research Unit

Seattle, Washington, 98101, United States

Location

MeSH Terms

Conditions

Myocardial Infarction; Stroke; Death, Sudden, Cardiac

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Infarction; Ischemia; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Necrosis; Cerebrovascular Disorders; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Heart Arrest; Death, Sudden; Death

Study Officials

• Bruce M. Psaty, MD, PhD

  University of Washington

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor, Medicine & Epidemiology

Study Record Dates

• First Submitted: December 12, 2007
• First Posted: December 13, 2007
• Study Start: September 1, 2007
• Primary Completion: November 1, 2016
• Study Completion: November 1, 2016
• Last Updated: November 9, 2016

Record last verified: 2016-11

Locations

US (1)